Does the media refer more to LUCD or AURA?

In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 1 articles in the media. Lucid Diagnostics' average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NGNE or LUCD?

In the previous week, Neurogene had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for Lucid Diagnostics. Neurogene's average media sentiment score of 0.49 beat Lucid Diagnostics' score of 0.00 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, LUCD or SVA?

Lucid Diagnostics has higher earnings, but lower revenue than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lucid Diagnostics $4.71M 36.20 -$58.01M -$0.47 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is LUCD or SVA more profitable?

Sinovac Biotech has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -959.76% N/A -119.57% Sinovac Biotech N/A N/A N/A

Does the media refer more to MNPR or LUCD?

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 1 articles in the media. Monopar Therapeutics' average media sentiment score of 0.27 beat Lucid Diagnostics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lucid Diagnostics (LUCD) Competitors

$0.84 -0.05 (-6.02%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.85 +0.01 (+1.08%)

As of 09/23/2026 07:42 PM Eastern

Compare

LUCD vs. SGMT, AURA, NGNE, SVA, and MNPR

Should you buy Lucid Diagnostics stock or one of its competitors? Lucid Diagnostics's main competitors and comparable companies include Sagimet Biosciences (SGMT), Aura Biosciences (AURA), Neurogene (NGNE), Sinovac Biotech (SVA), and Monopar Therapeutics (MNPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lucid Diagnostics compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Sagimet Biosciences has a beta of 3.45, indicating that its stock price is 245% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Sagimet Biosciences has higher earnings, but lower revenue than Lucid Diagnostics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	N/A	N/A	-$51.04M	-$1.28	N/A
Lucid Diagnostics	$4.71M	36.20	-$58.01M	-$0.47	N/A

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sagimet Biosciences has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Sagimet Biosciences presently has a consensus target price of $27.96, indicating a potential upside of 168.32%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 399.17%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Lucid Diagnostics had 1 more articles in the media than Sagimet Biosciences. MarketBeat recorded 1 mentions for Lucid Diagnostics and 0 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score.

Company	Overall Sentiment
Sagimet Biosciences	Neutral
Lucid Diagnostics	Neutral

Summary

Sagimet Biosciences beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Lucid Diagnostics compare to Aura Biosciences?

Lucid Diagnostics (NASDAQ:LUCD) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Lucid Diagnostics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	36.20	-$58.01M	-$0.47	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Lucid Diagnostics currently has a consensus target price of $4.19, suggesting a potential upside of 399.17%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 190.70%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, research analysts clearly believe Lucid Diagnostics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lucid Diagnostics has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Aura Biosciences	N/A	-73.18%	-62.00%

In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 1 articles in the media. Lucid Diagnostics' average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lucid Diagnostics beats Aura Biosciences on 10 of the 13 factors compared between the two stocks.

How does Lucid Diagnostics compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lucid Diagnostics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	665.49	-$90.35M	-$5.03	N/A
Lucid Diagnostics	$4.71M	36.20	-$58.01M	-$0.47	N/A

Neurogene currently has a consensus price target of $83.67, indicating a potential upside of 170.50%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 399.17%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Neurogene had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for Lucid Diagnostics. Neurogene's average media sentiment score of 0.49 beat Lucid Diagnostics' score of 0.00 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Neurogene has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Summary

Neurogene beats Lucid Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Sinovac Biotech?

Lucid Diagnostics (NASDAQ:LUCD) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Sinovac Biotech has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Sinovac Biotech	N/A	N/A	N/A

Lucid Diagnostics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lucid Diagnostics currently has a consensus target price of $4.19, suggesting a potential upside of 399.17%. Sinovac Biotech has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Given Lucid Diagnostics' higher probable upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Lucid Diagnostics has higher earnings, but lower revenue than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	36.20	-$58.01M	-$0.47	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

In the previous week, Lucid Diagnostics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for Lucid Diagnostics and 0 mentions for Sinovac Biotech. Lucid Diagnostics' average media sentiment score of 0.00 equaled Sinovac Biotech'saverage media sentiment score.

Company	Overall Sentiment
Lucid Diagnostics	Neutral
Sinovac Biotech	Neutral

Summary

Lucid Diagnostics beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

How does Lucid Diagnostics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Monopar Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Monopar Therapeutics presently has a consensus target price of $121.36, indicating a potential upside of 35.78%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 399.17%. Given Lucid Diagnostics' higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Monopar Therapeutics has higher earnings, but lower revenue than Lucid Diagnostics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Lucid Diagnostics	$4.71M	36.20	-$58.01M	-$0.47	N/A

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 1 articles in the media. Monopar Therapeutics' average media sentiment score of 0.27 beat Lucid Diagnostics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Lucid Diagnostics	-959.76%	N/A	-119.57%

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Monopar Therapeutics beats Lucid Diagnostics on 9 of the 15 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$181.42M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.78	13.88	274.07	25.69
Price / Sales	36.20	1,356.95	643.13	79.17
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-2.71	15.40	10.47	6.32
Net Income	-$58.01M	-$22.82M	$3.49B	$359.73M
7 Day Performance	7.50%	-1.71%	-0.67%	0.17%
1 Month Performance	-16.11%	-6.18%	-3.17%	-3.27%
1 Year Performance	-19.34%	30.64%	15.13%	5.58%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	2.1972 of 5 stars	$0.84 -6.0%	$4.19 +399.2%	-20.5%	$181.42M	$4.71M	N/A	82
SGMT Sagimet Biosciences	3.133 of 5 stars	$11.09 +2.7%	$27.96 +152.1%	+54.8%	$671.31M	$2M	N/A	16
AURA Aura Biosciences	1.6126 of 5 stars	$6.45 +1.4%	$17.50 +171.3%	-3.2%	$659.56M	N/A	N/A	113
NGNE Neurogene	2.4129 of 5 stars	$33.60 +3.2%	$83.67 +149.0%	+83.6%	$651.77M	$930K	N/A	131	High Trading Volume
SVA Sinovac Biotech	0.9139 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.66M	$386.01M	N/A	3,008	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. SGMT, AURA, NGNE, SVA, and MNPR

How does Lucid Diagnostics compare to Sagimet Biosciences?

Summary

How does Lucid Diagnostics compare to Aura Biosciences?

Summary

How does Lucid Diagnostics compare to Neurogene?

Summary

How does Lucid Diagnostics compare to Sinovac Biotech?

Summary

How does Lucid Diagnostics compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. SGMT, AURA, NGNE, SVA, and MNPR

How does Lucid Diagnostics compare to Sagimet Biosciences?

Which has more risk & volatility, SGMT or LUCD?

Which has higher earnings and valuation, SGMT or LUCD?

Do insiders and institutionals hold more shares of SGMT or LUCD?

Is SGMT or LUCD more profitable?

Do analysts rate SGMT or LUCD?

Does the media prefer SGMT or LUCD?

Summary

How does Lucid Diagnostics compare to Aura Biosciences?

Which has preferable earnings & valuation, LUCD or AURA?

Do analysts rate LUCD or AURA?

Which has more volatility and risk, LUCD or AURA?

Do insiders and institutionals hold more shares of LUCD or AURA?

Is LUCD or AURA more profitable?

Does the media refer more to LUCD or AURA?

Summary

How does Lucid Diagnostics compare to Neurogene?

Do insiders & institutionals believe in NGNE or LUCD?

Which has better valuation and earnings, NGNE or LUCD?

Do analysts rate NGNE or LUCD?

Does the media prefer NGNE or LUCD?

Is NGNE or LUCD more profitable?

Which has more risk and volatility, NGNE or LUCD?

Summary

How does Lucid Diagnostics compare to Sinovac Biotech?

Is LUCD or SVA more profitable?

Which has more volatility and risk, LUCD or SVA?

Do insiders & institutionals hold more shares of LUCD or SVA?

Do analysts prefer LUCD or SVA?

Which has better earnings and valuation, LUCD or SVA?

Does the media favor LUCD or SVA?

Summary

How does Lucid Diagnostics compare to Monopar Therapeutics?

Which has more risk & volatility, MNPR or LUCD?

Do analysts rate MNPR or LUCD?

Which has stronger valuation and earnings, MNPR or LUCD?

Does the media refer more to MNPR or LUCD?

Is MNPR or LUCD more profitable?

Do institutionals & insiders believe in MNPR or LUCD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools